We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

altona Diagnostics GmbH

altona Diagnostics GmbH develops and commercializes real-time PCR based assays and molecular diagnostic test solution... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
22 May 2021 - 26 May 2021
Virtual Venue
25 May 2021 - 28 May 2021

Prolonged Maternal Zika Viremia Evaluated for Adverse Perinatal Outcomes

By LabMedica International staff writers
Posted on 10 Feb 2021
Print article
Image: The RealStar Zika Virus RT-PCR Kit 1.0 is an in vitro diagnostic test, based on real-time PCR technology, for the qualitative detection of Zika virus specific RNA in human serum or urine (Photo courtesy of Altona Diagnostics).
Image: The RealStar Zika Virus RT-PCR Kit 1.0 is an in vitro diagnostic test, based on real-time PCR technology, for the qualitative detection of Zika virus specific RNA in human serum or urine (Photo courtesy of Altona Diagnostics).
The recent worldwide epidemic confirmed maternal–fetal transmission of Zika virus (ZIKV) and its association with adverse perinatal outcomes, particularly severe central nervous system lesions and fetal losses.

ZIKV is detectable in maternal blood by reverse transcription polymerase chain reaction (RT-PCR) during the acute phase of infection. ZIKV viremia usually lasts from two days before to 16 days after symptom onset. The median time of ZIKV RNA clearance is five days.

A team of medical scientists led by those at Lausanne University Hospital (Lausanne, Switzerland) carried out a prospective cohort study in French Guiana and enrolled Zika virus–infected pregnant women with a positive PCR result at inclusion and non-infected pregnant women; both groups underwent serologic testing in each trimester and at delivery during January–July 2016. Prolonged viremia was defined as ongoing virus detection >30 days post-infection.

The team performed molecular and serologic testing using the RealStar Zika Kit (Altona Diagnostics GmbH, Hamburg, Germany) for RT-PCR, in-house IgM and IgG antibody-capture ELISA, and microneutralization assays for serologic testing. The limit of detection for serum samples tested using the RealStar Zika Kit was 0.61 copies/μL (95% CI 0.39–1.27). A cycle threshold (Ct) value <37 was considered positive.

The team reported that adverse outcomes (fetal loss or neurologic anomalies) were more common in fetuses and neonates from mothers with prolonged viremia (40.0%) compared with those from infected mothers without prolonged viremia (5.3%, adjusted relative risk [aRR] 7.2 [95% CI 0.9–57.6]) or those from non-infected mothers (6.6%, aRR 6.7 [95% CI 3.0–15.1]). Congenital infections were confirmed more frequently in fetuses from mothers with prolonged viremia (9/15 [60.0%]) when compared with those from infected mothers without prolonged viremia (5/19 [26.3%], RR 2.3 [95% CI 1.0–5.4]) and non-infected mothers (0/332 [0.0%]).

The authors concluded that prolonged maternal ZIKV viremia could be a marker for an increased risk for maternal–fetal transmission and subsequent adverse perinatal outcomes. Even if prolonged maternal viremia is not consistently present in cases of congenital infection, it might reflect active viral replication in the fetal–placental compartment and should lead to an enhanced prenatal and neonatal follow-up. The study was published in the February 2021 issue of the journal Emerging Infectious Diseases.

Related Links:
Lausanne University Hospital
Altona Diagnostics GmbH


New
Gold Supplier
Integrated Immunoassay & Chemistry System
Dimension EXL with LM
New
Lateral Flow Test Reader
BSX READER
New
Silver Supplier
Influenza A/B Test (Colloidal Gold-based)
Influenza A/B Test (Colloidal Gold-based)
New
Molecular Diagnostic System
Molecular Diagnostic System

Print article
BIOHIT  Healthcare OY
Mayo Medical Laboratories

Channels

Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.